Enanta Pharmaceuticals (NASDAQ:ENTA) Issues Quarterly Earnings Results, Beats Estimates By $0.11 EPS

Enanta Pharmaceuticals (NASDAQ:ENTA) issued its quarterly earnings results on Monday. The biotechnology company reported ($1.05) EPS for the quarter, beating the consensus estimate of ($1.16) by $0.11, Zacks reports. Enanta Pharmaceuticals had a negative net margin of 171.57% and a negative return on equity of 73.02%.

Enanta Pharmaceuticals Price Performance

Enanta Pharmaceuticals stock opened at $5.59 on Wednesday. The stock has a market cap of $119.23 million, a price-to-earnings ratio of -1.02 and a beta of 0.54. Enanta Pharmaceuticals has a 1 year low of $4.71 and a 1 year high of $17.80. The firm has a 50-day moving average of $5.87 and a two-hundred day moving average of $9.61.

Insider Buying and Selling at Enanta Pharmaceuticals

In related news, CEO Jay R. Luly sold 5,142 shares of the stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $8.06, for a total transaction of $41,444.52. Following the completion of the sale, the chief executive officer now owns 801,638 shares of the company’s stock, valued at $6,461,202.28. This represents a 0.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 13.89% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts recently commented on ENTA shares. Robert W. Baird cut their price target on shares of Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a report on Tuesday, November 26th. JMP Securities reiterated a “market outperform” rating and set a $21.00 price target on shares of Enanta Pharmaceuticals in a report on Tuesday. StockNews.com downgraded shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday. Finally, HC Wainwright reiterated a “buy” rating and set a $18.00 price target on shares of Enanta Pharmaceuticals in a report on Tuesday. Two research analysts have rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $17.25.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.